Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Chartapisak, Wattana ^b   Opastirakul, Sauwalak ^b   Hodson, Elisabeth M ^a   Willis, Narelle S ^c   Craig, Jonathan C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYPROHEPTADINE; DIPYRIDAMOLE; HEPARIN; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; SALICYLIC ACID;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANAPHYLACTOID PURPURA; BEHAVIOR DISORDER; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATURIA; HUMAN; HYPERTENSION; INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; PROTEINURIA; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 70049112126     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005128.pub2     Document Type: Review

References (42)

1. * Dudley J, Smith G, Llewellyn-Edwards A, Tizard EJ. Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Schonlein Purpura Nephritis [abstract]. Pediatric Nephrology 2007;22:1457.
2. Smith G. Randomised, double-blind, placebo controlled study to determine whether steroids reduce the development of nephropathy in Henoch-Schonlein purpura. National Research Register, UK [https://portal.nihr.ac.uk/Profiles/NRR. aspx?Publication-ID=M0048086115] 2002. [CENTRAL: CN-00449954]
3. * Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisolone in early Henoch Schonlein purpura [ISRCTN85109383]. BMC Medicine 2004; Vol.2, issue 7. [DOI: 10.1186/1741-7015-2- 7]
4. * Islek I, Sezer T, Totan M, Cakir M, Kucukoduk S. The effect of profilactic prednisolon therapy on renal involvement in henoch schoenlein vasculitis. XXXVI Congress of the European Renal Association European Dialysis & Transplant Association; 1999 Sep 5-8; Madrid (Spain). 1999:103. [CENTRAL: CN-00484464]
5. * Mollica F, Li VS, Garozzo R, Russo G. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. European Journal of Pediatrics 1992;151(2):140-144 [MEDLINE: 1343079]
6. * Peratoner L, Longo F, Lepore L, Freschi P. Prophylaxis and therapy of glomerulonephritis in the course of anaphylactoid purpura. The results of a polycentric clinical trial. Acta Paediatrica Scandinavica 1990;79(10):976-977 [MEDLINE: 2264475]
7. * Ronkainen J, Koskimies O, Ala-Houhala M, Antkainen M, Merenmies J, Rajantie J, et al.Early prednisone therapy in Henoch-Schonlein purpura: a randomized double-blind, placebo-controlled trial. Journal of Pediatrics 2006;149(2):241-247 [MEDLINE: 16887443]
8. * Ronkainen J, Ala-Houhala M, Antkainen M, Jahnukainen T, Koskimies O, Merenmies J, et al.Cyclosporine A (CyA) versus MP pulses (MP) in the treatment of severe Henoch-Schonlein Nephritis (HSN) [abstract]. Pediatric Nephrology 2006;21(10):1531.
9. * Tarshish P, Bernstein J, Edelmann CM Jr. Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatric Nephrology 2004;19(1):51-56 [MEDLINE: 14634864]
10. * Yanyan H, Hongmei S, Lihua S, Min W. Preventive value of heparin on the occurrence of nephropathy in Henoch-Schoenlein Purpura: a randomized controlled clinical trial [abstract]. 23rd International Congress of Paediatrics; 2001 Sep 9-14; Beijing (China). 2001. [CENTRAL: CN-00462028]
11. * Yoshimoto M, Ito H, Shindo S, Yamashita F. Evaluation of the preventive role of dipyridamoleant aspirin against renal complication in Schonlein-Henoch purpura [abstract]. Pediatric Nephrology 1987;1(1):C47. [CENTRAL: CN-00445875]
12. * Yoshimoto M, Ito H, Shindo S, Yamashita F. Evaluation of the preventive role of dipyridamole and aspirin against renal complication in Schonlein-Henoch purpura [abstract]. Pediatric Nephrology 1987;1:C47. [CENTRAL: CN-00445875]
13. Jin ZD, Wang SC, Sun YQ, et al.Effect of Danshao granule on serum superoxide dismutase activity andmalonyldialdehyde content in children with Henoch-Schonlein purpura nephritis. Zhongguo Zhongxiyi Jiehe Zqzhi [Chinese Journal of Integrated Traditional & Western Medicine] 2003;23(12):905-907
14. * Yu YH. Treatment of purpuric nephritis in children with Tripterygium Wilfordii Polyglucoside and Radix Salviae Miltiorrhizae [abstract]. Pediatric Nephrology 2001;16:C78.
15. Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clinical Nephrology 1998;49(1):9-14. [MEDLINE: 9491279] (Pubitemid 28043360)
16. Chalmers TC, Celano P, Sacks HS, Smith H. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine 1983;309(22):1358-1361 [MEDLINE: 6633598] (Pubitemid 14246558)
17. Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch-Schonlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. American Journal of Nephrology 2001;18(4):347-350 [MEDLINE: 11359020]
18. Foster BJ, Bernard C, Drummond KN, Sharma AK. Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. Journal of Pediatrics 2000;136(3):370-375 [MEDLINE: 10700695] (Pubitemid 30470961)
19. Garner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002;360(9341):1197-1202 [MEDLINE: 12401245] (Pubitemid 35232718)
20. Goldstein AR, White RHW, Akuse R, Chantler C. Long term follow up of childhood Henoch Schonlein nephritis. Lancet 1992;339(8788):280-282 [MEDLINE: 1346291]
21. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-560 [MEDLINE: 12958120]
22. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
23. Iijima R, Ito-Kariya S, Nakamura H, Yoshikowa N. Multiple combined therapy for severe Henoch Schonlein nephritis in children. Pediatric Nephrology 1998;12(3):244-248 [MEDLINE: 9630047] (Pubitemid 28204134)
24. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross W, et al.Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis & Rheumatism 1994;37(2):187-192 [MEDLINE: 8129773] (Pubitemid 24065492)
25. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
26. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Archives of Disease in Childhood 2005;90(9):916-920 [MEDLINE: 15871983] (Pubitemid 41232341)
27. Niaudet P, Murcia I, Beaufils H, Broyer M, Habib R. Primary IgA nephropathies in children: prognosis and treatment. Advances in Nephrology From the Necker Hospital 1993;2:121-140 [MEDLINE: 8427055]
28. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatric Nephrology 1998;12(3):238-243 [MEDLINE: 9630046] (Pubitemid 28204133)
29. Willis NS, Mitchell R, Higgins GY, Webster AC, Craig JC. Cochrane Renal Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2009, Issue 1. Art. No.: RENAL (accessed March 2009).
30. Ronkainen J, Ala- Houhala M, Huttunen NP, Jahnukainen T, Koskimies O, Ormala T, et al.Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. Clinical Nephrology 2003;60(2):80-84 [MEDLINE: 12940608] (Pubitemid 36975181)
31. Saulsbury FT. Henoch-Schonlein Purpura in children. Report of 100 patients and review of the literature. Medicine 1999;78(6):395-409. [MEDLINE: 10575422]
32. Schulz KF. Chalmers I. Hayes RJ. Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-412 [MEDLINE: 7823387]
33. Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatric Nephrology 2007;22(8):1167-1171 [MEDLINE: 17530298]
34. Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schonlein purpura. Scandinavian Journal of Rheumatology 2006;35(1):56-60. [MEDLINE: 16467044]
35. Steward M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schonlein purpura in an unselected childhood population. European Journal of Pediatrics 1998;147(2):113-115 [MEDLINE: 3366130]
36. Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S. Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatric Nephrology 2003;18(4):347-350 [MEDLINE: 12700960] (Pubitemid 36790072)
37. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schonlein purpura: a systematic review. Pediatrics 2007;120(5):1079-1087 [MEDLINE: 17974746] (Pubitemid 350085543)
38. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-605 [MEDLINE: 18316340]
39. Wyatt RJ, Hogg RJ. Evidence-based assessment of treatment options for children with IgA nephropathies. Pediatric Nephrology 2001;16(2):156-67. [: 11261686]
40. Zaffanello M, Brugnara M, Franchini M. Therapy for children with henoch-schonlein purpura nephritis: a systematic review. Thescientificworldjournal 2007;7:20-30. [MEDLINE: 17221139] (Pubitemid 46104911)
41. Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating renal disease in Henoch-Schönlein Purpura (HSP). Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD005128]
42. Chartapisak W, Opastirakul O, Willis NS, Craig JC, Hodson EM. Prevention and treatment of renal disease in Henoch-Schönlein Purpura: a systematic review. Archives of Disease in Childhood 2008;94(2):132-137 [MEDLINE: 18701559]